New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2013
07:32 EDTPTNPalatin Tech announces notification of patent allowance
Palatin Technologies announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/472,914. The application includes composition of matter claims on two of Palatin's most advanced melanocortin receptor-1 specific peptides. Palatin is conducting in vitro and animal in vivo studies with the peptides claimed in the allowed patent and with related peptides. Proposed indications under study include dermatologic indications such as vitiligo and erythropoietic protoporphyria, inflammatory bowel disease, ocular indications such as uveitis and dry eye, and nephritis and other kidney conditions. Palatin plans to designate an initial clinical lead peptide candidate in the first half of 2013 and start toxicology and other preclinical studies preparatory to filing an Investigational New Drug Application with the U.S. Food and Drug Administration.
News For PTN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
07:34 EDTPTNPalatin Tech reports Q1 EPS 1c, consensus 1c
Subscribe for More Information
November 17, 2014
16:33 EDTPTNPalatin Tech requests withdrawal of registration statement
The company has determined, due to market conditions, not to proceed at this time with the registration and sale of common stock as contemplated by the Registration Statement, File No. 333-198992.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use